Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Clinical role
Segmentation, quantitative post-processing and follow-up comparison
Images and patients
MRI · Brain
Key limitation
Keep in mind: Quantitative post-processing assists clinician evaluation. WMH follow-up permits changes in field strength, pixel spacing and slice thickness in VA60; a field-strength difference produces an information message.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: T1 MPRAGE for brain morphometry. The VA60 comparison table specifies T2-weighted 3D FLAIR alone for WMH, with WMH follow-up at 1.5 T and 3 T and Siemens, GE and Philips inputs.
Who uses it?Intended users: Healthcare professionals familiar with post-processing magnetic resonance images.
What does the software produce?Output: Absolute and normalized brain-structure volumes, age-matched normative comparisons and deviation/label maps; WMH count and volume in four brain regions, maps of new or enlarged WMH on follow-up, and numeric/visual reports sent to PACS.
What is its most important limitation?Key limitation: Quantitative post-processing assists clinician evaluation. WMH follow-up permits changes in field strength, pixel spacing and slice thickness in VA60; a field-strength difference produces an information message.
Clinical takeaway. Clinical role: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Evidence takeaway. Evidence from the reviewed source record: VA60 WMH testing used 100 subjects and follow-up testing used 165 subjects, with manually annotated reference data. Morphometry and morphometry follow-up were unchanged from the predicate. Testing supports the modified quantitative features, not a new prospective outcome benefit.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
T1 MPRAGE for brain morphometry. The VA60 comparison table specifies T2-weighted 3D FLAIR alone for WMH, with WMH follow-up at 1.5 T and 3 T and Siemens, GE and Philips inputs.
Exact FDA submission
Checked 2026-09-06
The specific VA60 input-data row streamlines the predecessor T1-plus-FLAIR requirement, although introductory prose still repeats the older combination. Do not use the older VA51 manual as the VA60 acquisition specification.
Absolute and normalized brain-structure volumes, age-matched normative comparisons and deviation/label maps; WMH count and volume in four brain regions, maps of new or enlarged WMH on follow-up, and numeric/visual reports sent to PACS.
Quantitative post-processing assists clinician evaluation. WMH follow-up permits changes in field strength, pixel spacing and slice thickness in VA60; a field-strength difference produces an information message.
Exact FDA submission
Checked 2026-09-05
This does not establish unrestricted mixing of acquisitions or that normative values from different software tools are interchangeable.
VA60 WMH testing used 100 subjects and follow-up testing used 165 subjects, with manually annotated reference data. Morphometry and morphometry follow-up were unchanged from the predicate. Testing supports the modified quantitative features, not a new prospective outcome benefit.
Exact FDA submission
Checked 2026-09-06
Preserves the baseline 100-subject cohort and adds the separately described 165-subject follow-up cohort; these are not pooled as unique patients.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
VA60 WMH testing used 100 subjects and follow-up testing used 165 subjects, with manually annotated reference data. Morphometry and morphometry follow-up were unchanged from the predicate. Testing supports the modified quantitative features, not a new prospective outcome benefit.
FDA source
Exact FDA submission
Checked 2026-09-06
Preserves the baseline 100-subject cohort and adds the separately described 165-subject follow-up cohort; these are not pooled as unique patients.
No product-wide VA60 clinical sensitivity is promoted. Segmentation/follow-up endpoints and an older tool-to-tool volumetry study are not interchangeable with diagnosis.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-06
No product-wide VA60 clinical specificity is established by the reviewed evidence.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K253057 WMH segmentation validation
DesignStandalone evaluation against manually annotated ground truth from three radiologists
Population100 subjects including multiple sclerosis, Alzheimer disease, cognitive impairment and healthy controls; 1.5 T/3 T Siemens, GE and Philips MRI
Validity Assessment of an Automated Brain Morphometry Tool for Patients with De Novo Memory Symptoms
DesignRetrospective comparison with FreeSurfer 7.1.1/Individual Longitudinal Participant processing and clinical impressions
PopulationT1-weighted MRI from 45 OASIS-4 participants with de novo memory symptoms
Scopeproduct family
Tested versionAI-Rad Companion Brain MR; no VA60 linkage in reviewed abstract
Samplen=45
IndependenceIndependence not established
PMID:36797031 · DOI:10.3174/ajnr.A7790
Strong correlation did not imply agreement of absolute volumes or standardized values across tools. No VA60 diagnostic sensitivity/specificity is inferred. Full-text disclosure review remains incomplete.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: T1 MPRAGE for brain morphometry. The VA60 comparison table specifies T2-weighted 3D FLAIR alone for WMH, with WMH follow-up at 1.5 T and 3 T and Siemens, GE and Philips inputs.
Scope: Exact FDA submission. The specific VA60 input-data row streamlines the predecessor T1-plus-FLAIR requirement, although introductory prose still repeats the older combination. Do not use the older VA51 manual as the VA60 acquisition specification.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Generated maps and reports can be exported to PACS; the summary describes confirmation and configuration UI components.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Absolute and normalized brain-structure volumes, age-matched normative comparisons and deviation/label maps; WMH count and volume in four brain regions, maps of new or enlarged WMH on follow-up, and numeric/visual reports sent to PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Absolute and normalized brain-structure volumes, age-matched normative comparisons and deviation/label maps; WMH count and volume in four brain regions, maps of new or enlarged WMH on follow-up, and numeric/visual reports sent to PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-06Last searched
21Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored metadata screened September 5. Primary author-institution abstract reviewed September 6 after PubMed/PMC verification barriers; retained as 45-participant family volumetry study, not VA60 results. Stored trial array was empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, vendor technical documentation, peer reviewed literature, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission
VA60 module, cloud/edge infrastructure, PACS integration and service prices are not established from reviewed materials.
Pricing model: Not verified - checked 2026-09-06 - Exact FDA submission
Per-case, module and enterprise terms require a version-specific quote.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Siemens Healthineers AI-Rad Companion reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-06 - Exact FDA submission
A predecessor data sheet is available, but exact VA60 onboarding, competency and support terms were not verified.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.